List of Figures
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics, Global, Clinical Trials by Region (%), 2018* 7
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 11
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 14
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018* 15
Proportion of Secondary Progressive Multiple Sclerosis (SPMS) to Central Nervous System Clinical Trials, G7 Countries (%), 2018* 16
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 18
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 19
Proportion of Secondary Progressive Multiple Sclerosis (SPMS) to Central Nervous System Clinical Trials, E7 Countries (%), 2018* 21
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 23
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 24
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics, Global, Clinical Trials by Phase (%), 2018* 25
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 26
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 27
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 29
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 30
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 31
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 32
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 34
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 36
GlobalData Methodology 158


List of Tables
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics, Global, Clinical Trials by Region, 2018* 7
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 11
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics Clinical Trials, North America, Top Countries, 2018* 13
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 14
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018* 15
Proportion of Secondary Progressive Multiple Sclerosis (SPMS) to Central Nervous System Clinical Trials, G7 Countries (%), 2018* 17
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 18
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 20
Proportion of Secondary Progressive Multiple Sclerosis (SPMS) to Central Nervous System Clinical Trials, E7 Countries (%), 2018* 22
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 23
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 24
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics, Global, Clinical Trials by Phase, 2018* 25
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 26
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 28
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 29
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 30
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 31
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 33
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 35
Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 37